Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis

Overview of attention for article published in Neurology, January 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
Good Attention Score compared to outputs of the same age and source (72nd percentile)

Mentioned by

blogs: 1 blog
policy: 1 policy source
twitter: 21 X users

facebook: 1 Facebook page
guideline: 1 clinical guideline source

Readers on

mendeley: 103 Mendeley

So far, Altmetric has seen 21 X posts from 21 X users, with an upper bound of 133,367 followers.

RT @neurochecklists: Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis https://t.co/V8a1…

Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis https://t.co/V8a1AdOBur

RT @GreenJournal: Class I evidence that for mild to moderate acetylcholine receptor antibody-positive generalized #MyastheniaGravis, compar…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 17 additional X posts.